Data presented at ASH illustrates that continued treatment with vidaza can benefit MDS patients

December 10, 2008

Crosswicks, NJ - (December 10, 2008) - The Myelodysplastic Syndromes (MDS) Foundation announced today that a new analysis of the AZA-001 phase III clinical trial demonstrates that continued treatment with VIDAZA (azacitidine) can improve response rates for higher-risk MDS patients.

Leading hematologist Dr. Lewis Silverman of Mount Sinai Medical Center presented the analysis at the 50th Annual Meeting of the American Society of Hematology. The results showed that 51% of patients in the trial responded to treatment with Vidaza. Of those patients, almost half achieved an improved response when treatment with VIDAZA was continued for an additional four cycles.

"We are encouraged by this analysis which for the first time shows that patients can benefit from continued treatment with VIDAZA," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "This analysis provides hope for many MDS patients that do not initially have a strong response to treatment. We look forward to additional studies that showcase the clinical potential of epigenetic therapies like VIDAZA."

Dr. Silverman's analysis is a follow-up to results from the AZA-001 trial, presented at the American Society of Clinical Oncology meeting in June, which showed that VIDAZA significantly extends overall survival for patients with MDS compared to conventional care regimens (CCR). Patients who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells, either red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.
-end-
About the MDS Foundation

The Myelodysplastic Syndromes Foundation, Inc. is a multi-disciplinary, international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases. For further information, please visit http://www.mds-foundation.org.

MDS Foundation

Related Blood Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

Method to derive blood vessel cells from skin cells suggests ways to slow aging
Salk scientists have used skin cells called fibroblasts from young and old patients to successfully create blood vessels cells that retain their molecular markers of age.

Cancer cells take over blood vessels to spread
In laboratory studies, Johns Hopkins Kimmel Cancer Center and Johns Hopkins University researchers observed a key step in how cancer cells may spread from a primary tumor to a distant site within the body, a process known as metastasis.

COVID-19 causes 'hyperactivity' in blood-clotting cells
Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease, according to University of Utah Health scientists.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Blood transfusions: Fresh red blood cells no better than older ones
Findings from the ABC-PICU study on critically ill children may alter policies at hospitals where fresh red cells are preferentially used.

Changes in blood flow tell heart cells to regenerate
Altered blood flow resulting from heart injury switches on a communication cascade that reprograms heart cells and leads to heart regeneration in zebrafish.

Impeding white blood cells in antiphospholipid syndrome reduced blood clots
A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition.

Study gives new perspective on production of blood cells and immune cells
A new study provides a thorough accounting of blood cell production from hematopoietic stem cells.

White blood cells related to allergies may also be harnessed to destroy cancer cells
A new Tel Aviv University study finds that white blood cells which are responsible for chronic asthma and modern allergies may be used to eliminate malignant colon cancer cells.

Read More: Blood Cells News and Blood Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.